The Price to Book ratio for Five Prime Therapeutics, Inc. NasdaqGS:FPRX is 2.536962. The Price to book ratio is the current share price of a company divided by the book value per share. A lower price to book ratio indicates that the stock might be undervalued. Similarly, Price to cash flow ratio is another helpful ratio in determining a company’s value. The Price to Cash Flow for Five Prime Therapeutics, Inc. (NasdaqGS:FPRX) is -5.997358. This ratio is calculated by dividing the market value of a company by cash from operating activities. Additionally, the price to earnings ratio is another popular way for analysts and investors to determine a company’s profitability. The price to earnings ratio for Five Prime Therapeutics, Inc. (NasdaqGS:FPRX) is -4.478755. This ratio is found by taking the current share price and dividing by earnings per share.

There are many traders who think that proper psychology is one of the most important aspects of becoming successful in the stock market. Traders may need to learn how to become confident while overcoming certain fears and dealing with extreme ups and downs. This may not be easy as individuals all draw off of prior experiences at some level. Being able to convert outside success to the stock market may take some work. Traders who are able to overcome previous bias may be on the right path for having the proper mindset when entering the market.

Further, we can see that Five Prime Therapeutics, Inc. (NasdaqGS:FPRX) has a Shareholder Yield of -0.017158 and a Shareholder Yield (Mebane Faber) of -0.20387. The first value is calculated by adding the dividend yield to the percentage of repurchased shares. The second value adds in the net debt repaid yield to the calculation. Shareholder yield has the ability to show how much money the firm is giving back to shareholders via a few different avenues. Companies may issue new shares and buy back their own shares. This may occur at the same time. Investors may also use shareholder yield to gauge a baseline rate of return.

Checking in on some valuation rankings, Five Prime Therapeutics, Inc. (NasdaqGS:FPRX) has a Value Composite score of 93. Developed by James O’Shaughnessy, the VC score uses five valuation ratios. These ratios are price to earnings, price to cash flow, EBITDA to EV, price to book value, and price to sales. The VC is displayed as a number between 1 and 100. In general, a company with a score closer to 0 would be seen as undervalued, and a score closer to 100 would indicate an overvalued company. Adding a sixth ratio, shareholder yield, we can view the Value Composite 2 score which is currently sitting at 92.

Five Prime Therapeutics, Inc. (NasdaqGS:FPRX) has a current MF Rank of 17984. Developed by hedge fund manager Joel Greenblatt, the intention of the formula is to spot high quality companies that are trading at an attractive price. The formula uses ROIC and earnings yield ratios to find quality, undervalued stocks. In general, companies with the lowest combined rank may be the higher quality picks.

There are many different tools to determine whether a company is profitable or not. One of the most popular ratios is the “Return on Assets” (aka ROA). This score indicates how profitable a company is relative to its total assets. The Return on Assets for Five Prime Therapeutics, Inc. (NasdaqGS:FPRX) is -0.335107. This number is calculated by dividing net income after tax by the company’s total assets. A company that manages their assets well will have a higher return, while a company that manages their assets poorly will have a lower return.

The Piotroski F-Score is a scoring system between 1-9 that determines a firm’s financial strength. The score helps determine if a company’s stock is valuable or not. The Piotroski F-Score of Five Prime Therapeutics, Inc. (NasdaqGS:FPRX) is 4. A score of nine indicates a high value stock, while a score of one indicates a low value stock. The score is calculated by the return on assets (ROA), Cash flow return on assets (CFROA), change in return of assets, and quality of earnings. It is also calculated by a change in gearing or leverage, liquidity, and change in shares in issue. The score is also determined by change in gross margin and change in asset turnover.

**Volatility/PI**

Stock volatility is a percentage that indicates whether a stock is a desirable purchase. Investors look at the Volatility 12m to determine if a company has a low volatility percentage or not over the course of a year. The Volatility 12m of Five Prime Therapeutics, Inc. (NasdaqGS:FPRX) is 65.480400. This is calculated by taking weekly log normal returns and standard deviation of the share price over one year annualized. The lower the number, a company is thought to have low volatility. The Volatility 3m is a similar percentage determined by the daily log normal returns and standard deviation of the share price over 3 months. The Volatility 3m of Five Prime Therapeutics, Inc. (NasdaqGS:FPRX) is 59.148800. The Volatility 6m is the same, except measured over the course of six months. The Volatility 6m is 96.292900.

The Price Index is a ratio that indicates the return of a share price over a past period. The price index of Five Prime Therapeutics, Inc. (NasdaqGS:FPRX) for last month was 1.03043. This is calculated by taking the current share price and dividing by the share price one month ago. If the ratio is greater than 1, then that means there has been an increase in price over the month. If the ratio is less than 1, then we can determine that there has been a decrease in price. Similarly, investors look up the share price over 12 month periods. The Price Index 12m for Five Prime Therapeutics, Inc. (NasdaqGS:FPRX) is 0.46754.

Investors may be interested in viewing the Gross Margin score on shares of Five Prime Therapeutics, Inc. (NasdaqGS:FPRX). The name currently has a score of 66.00000. This score is derived from the Gross Margin (Marx) stability and growth over the previous eight years. The Gross Margin score lands on a scale from 1 to 100 where a score of 1 would be considered positive, and a score of 100 would be seen as negative.

**Receive News & Ratings Via Email** - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with MarketBeat.com's FREE daily email newsletter.